Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.
about
Follicular lymphoma: 2012 update on diagnosis and managementUpdate on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphoma90 Y-ibritumomab tiuxetan: a nearly forgotten opportunityrFluorescent imaging of cancerous tissues for targeted surgery.Follicular lymphoma: 2011 update on diagnosis and managementFollicular lymphoma: 2014 update on diagnosis and managementRadioimmunotherapy in relapsed follicular lymphoma previously treated by autologous bone marrow transplant: a report of eight new cases and literature review.Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomabEfficacy and safety of yttrium-90 ibritumomab tiuxetan in Japanese patients with non-Hodgkin lymphoma.Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides.Follicular lymphoma: still Six characters in search of an author?FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90Yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases.PEGylation enables the specific tumor accumulation of a peptide identified by phage display.Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.Cancer radioimmunotherapy.(90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma.Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.Long term efficacy and safety of Fludarabine, Cyclophosphamide and Rituximab regimen followed by (90)Y-ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphomaActivating Photodynamic Therapy in vitro with Cerenkov Radiation Generated from Yttrium-90.Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma.Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy.Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors.Treatment of follicular lymphoma: current status.Role of hematopoietic stem cell transplant in the management of follicular lymphoma.Phase 2 study of CHOP-R-14 followed by 90Y-ibritumomab tiuxetan in patients with previously untreated diffuse large B-cell lymphoma.Radioactive antibodies: a historical review of selective targeting and treatment of cancer.Biology and treatment of follicular lymphoma.Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report.Allogeneic stem cell transplantation in follicular lymphoma.Rituximab maintenance versus radioimmunotherapy consolidation in follicular lymphoma: which, when, and for whom?Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients.A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90 yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma.Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study.Advancing radioimmunotherapy and its future role in non-Hodgkin lymphoma.Antibody-mediated delivery of therapeutics for cancer therapy.Applying near-infrared photoimmunotherapy to B-cell lymphoma: comparative evaluation with radioimmunotherapy in tumor xenografts.Heterogeneity of intratumoral (111)In-ibritumomab tiuxetan and (18)F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin's lymphoma.Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results.Follicular lymphoma: 2015 update on diagnosis and management.
P2860
Q22252956-046D7432-94C9-4AD1-B798-524D4062DD66Q24633710-1B4104DD-291D-45A7-84C0-9E3C5AF8B31DQ26776480-E551413D-7020-4A0C-B6E7-27DCA842A909Q26830905-14465CEF-7732-4F74-BD05-AB4A498C5595Q26851450-B2F2D049-495C-4C2E-939E-1CE543B7C775Q27021850-51D5BA6E-2706-4586-9CF6-CF6E5BB1CE24Q33380518-E0496EB0-71BD-430E-AC51-6F6A7016B52FQ33392939-09765980-AED5-4026-8FCD-E83676378849Q33402171-E1765F5A-3707-4FBD-BC32-356DDA6AA0EEQ33645793-5EBB3CCA-6780-4DFD-AA6E-0848A7FC2796Q33927978-91C1BFA3-E23D-43A3-876B-DEDBF908498EQ34585773-F0E5B517-03E7-4C51-BCE7-17AA4AD95C73Q34615563-72A445A1-C419-4EB5-91CA-0C17749B42BAQ34700655-C3D128FA-911D-4099-A913-FB2393326CBDQ35070045-405516DE-6AE8-43BE-BCB8-DBE405832074Q35115650-2619C8FE-C32F-4446-B975-95792C9C6A03Q35780034-781BECBA-8C03-43DF-8B75-BDA44DC526FFQ35786490-7007894F-8E04-4B8A-8383-A7CCF4BB61DCQ36092165-1FF0A344-A9FC-45D6-B987-44ACDD912414Q36950052-971B76BC-6387-4AD7-ACFF-B7833C766639Q36979699-626265CA-D45F-411F-9913-F19FC9FA3282Q37169112-C58BAA74-4933-4B22-9867-AEBB013C56D1Q37259751-C4BBB8BD-1855-4A22-997C-DFB2E8B6E782Q37280915-BB258F54-DB65-488F-A283-F9AE078EC07BQ37533977-2AB97123-7B7A-43A3-9923-9AB64EA10F78Q37731964-F3BFE9D1-8616-4062-AC21-45B697928F2BQ37796519-8F55AA3A-9E56-4FD7-970A-D8994C879101Q37810118-04C1B846-23FB-46E1-9976-A17A8F64AD86Q37877728-DA22C5B6-92AA-4AF6-92D7-84C19B239B6DQ37887151-A86848A1-BB18-4F87-93E5-BEB9DB186536Q37930456-2679D18A-C170-4452-9725-A2501B228059Q38174058-0CA807CB-7799-4BF0-8BD3-29E323D5372AQ38259725-AAC37659-0BCE-43F5-A744-94BEF5FBA665Q38396244-4B69C9AE-333A-4962-A3EF-723DF2F0BA1EQ38473731-4A307D44-9B05-4434-9F67-6AA39F907227Q38665425-5E224F03-5545-40B7-819C-A783CF3D3765Q38696425-970E4B09-3746-4D94-9944-F2FF0FE2FFC1Q39224455-E49ED0D2-9CD7-4719-9AB5-F92C2CEB83B2Q39768589-DE52F047-9161-44D2-A856-4F1BC40FB255Q40122693-874C6F89-72BB-4397-A2B2-BB63E7D92E6D
P2860
Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Long-term responses in patient ...... trium 90 ibritumomab tiuxetan.
@en
Long-term responses in patient ...... trium 90 ibritumomab tiuxetan.
@nl
type
label
Long-term responses in patient ...... trium 90 ibritumomab tiuxetan.
@en
Long-term responses in patient ...... trium 90 ibritumomab tiuxetan.
@nl
prefLabel
Long-term responses in patient ...... trium 90 ibritumomab tiuxetan.
@en
Long-term responses in patient ...... trium 90 ibritumomab tiuxetan.
@nl
P2093
P356
P1433
P1476
Long-term responses in patient ...... trium 90 ibritumomab tiuxetan.
@en
P2093
Arturo Molina
Christos Emmanouilides
Gregory A Wiseman
Ian W Flinn
Mohamed Darif
Roger Macklis
Russell J Schilder
Thomas E Witzig
P304
P356
10.1002/CNCR.22617
P407
P50
P577
2007-05-01T00:00:00Z